Pharmaceuticals & Big Health

With China’s largest production base for insulin and enzymes, TEDA is the core area of the biomedical industry in Tianjin and even the Bohai area. After over 30 years of development, the prototype of the industrial chain including biopharmaceuticals, chemical medicines, traditional Chinese medicines, natural medicines, medical devices, in vitro diagnostics, pharmaceutical R&D outsourcing, biotechnology and other health products has been initially formed, which has been an important force supporting regional economic growth.

So far, TEDA has formed a pharmaceuticals and big health industrial cluster integrating biopharmaceutical, medical devices, pharmaceutical R&D outsourcing, food and drink, and big health. It has gathered a large number of high-quality companies such as Novo Nordisk, Servier, Glaxo Smith Kline, Casymchem, CanSino Biologics, WuXi AppTec, Mars, Nestlé, Coca-Cola, Meiji, etc. The products cover biological medicine, chemical medicine, medical consumables, food and beverage and other fields.

In 2019, biomedical industrial cluster in TEDA was successfully selected as the first batch of national strategic emerging industrial clusters by the National Development and Reform Commission and is listed in the key developing areas of national biomedical industry.

Over the years, pharmaceuticals & big health industry in TEDA has grown steadily. With about 50 billion yuan yielded from the industry in 2019, TEDA is home to accumulatively more than 800 such companies. In 2019, the industrial output value of the biopharmaceuticals was about 30 billion yuan, accounting for more than half of that of Tianjin.

Efforts should be made to improve the services of pharmaceuticals & big health industry park in line with Shanghai Zhangjiang Medicine Valley and Suzhou BioBAY, and to promote professional services including CRO/CDMO service, product registration, product testing, technical cooperation, instrument sharing, clinical cooperation, etc. and characteristic services including intellectual property, talent introduction, technology finance, industry and commerce registration, legal consultation, etc. It is committed to creating growth ecosphere and innovation ecosphere of five-in-one pharmaceuticals & big health industry including platform, think tank, capital, brand and service.

Industrial Regional Layout

It tries to make incubation in TEDA East, manufacturing in TEDA West, expansion of TEDA Middle Zone, and gradient development of TEDA Industrial Park and Nangang Industrial Zone;

Unique Location Advantage

As a concentrated area of biomedical health industry in northern China, Beijing-Tianjin-Hebei region is led by Beijing Zhongguancun. The surrounding areas and cities take over its talents and industrialization overflow. In terms of industrialization, Tianjin, as a national R&D base for advanced manufacturing, a hub for international shipping in North China and a demonstration area for financial innovation and services, has unique advantages in undertaking high-end manufacturing in North China. By strengthening the linkage with Beijing, conducting in-depth industrial cooperation, and leveraging its strengths in high-end manufacturing and logistics, Tianjin can pinpoint its positioning for the development of pharmaceuticals & big health industry in the Beijing-Tianjin-Hebei region.

Comprehensive Industrial Layout and Good Foundation

The pharmaceuticals & big health industrial chain in TEDA has initially formed. Since 1998, except for some years, the growth rate of output value of the biomedical manufacturing industry has been ahead of the overall industrial level of the region for a long time, and its positive driving effect on the industrial growth in the region has continued to increase. The comprehensive industrial layout gives TEDA more comprehensive competitiveness.

Over the years, TEDA has formulated dozens of support policies for comprehensive development of biomedical industry, including the pilot of policies in free trade zone, support policies for biomedicine R&D in comprehensive bonded zone, policies for science & technology innovation in TEDA, support policies for industrialization, policies on talent pool, funds of incubation and major high-tech technology project funding.

There are more than 30 provincial-level and above research institutions in the field of biomedical health in TEDA. In 2019, TEDA was shortlisted in the top 50 in the comprehensive competitiveness of bio-pharmaceutical industrial parks around the country. So far, there are state-owned investment incubation and transformation carriers covering about 200,000 square meters, such as TEDA Biomedical R&D Building, Rongsheng Building (located in TEDA West), Rongtong Building (base of big health), Tianda Science Park, and Rongjian Building, and various cooperative park carriers covering about 180,000 square meters, such as the International Biomedicine Innovation Park jointly built by the ministry and the municipality, the International Joint Academy of Biomedicine, Alexander Science Incubator, and TEDA SME Science Park. At the same time, a 1-square-kilometer transformation base for bio-pharmaceutical industry is being built in TEDA West.

Representative Companies